Results 261 to 270 of about 126,887 (307)
Macrophage repolarization by immune checkpoint blockade drives T cell engagement in the tumor microenvironment. [PDF]
iScienceKwok T +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Beyond immune checkpoint blockade: emerging immunological strategies
Nature Reviews Drug Discovery, 2021The success of checkpoint inhibitors has accelerated the clinical implementation of a vast mosaic of single agents and combination immunotherapies. However, the lack of clinical translation for a number of immunotherapies as monotherapies or in combination with checkpoint inhibitors has clarified that new strategies must be employed to advance the ...
Shawn P. Kubli +4 more
openaire +4 more sources
Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Immune Checkpoint Blockade in Malignant Mesothelioma
Seminars in Oncology, 2015Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient ...
Calabro' L, Maio M.
openaire +3 more sources
Combined Immune Checkpoint Blockade
Seminars in Oncology, 2015There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire +2 more sources
Presurgical immune checkpoint blockade
Science, 2020Cancer Immunotherapy Checkpoint blockade immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al.
openaire +1 more source
Delivery Strategies for Immune Checkpoint Blockade
Advanced Healthcare Materials, 2018AbstractImmune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers.
Qian Chen +4 more
openaire +2 more sources